Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.45 |
| ▸ | KLK7 | P49862 | 6/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724586 | 0.80 | CETP (0.51) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL1721862 | 0.74 | CETP (0.46) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL13609119 | 0.73 | CETP (0.58) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL3942600 | 0.73 | CETP (0.58) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL759185 | 0.71 | CETP (0.52) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL9885652 | 0.71 | CETP (0.52) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL3950021 | 0.70 | CETP (0.57) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL1724982 | 0.70 | KLK7 (0.52) | CETPKLK7KLK5GPR119NR1H2 | |
| SCHEMBL1723542 | 0.69 | CETP (0.62) | CETP | |
| SCHEMBL757682 | 0.69 | CETP (0.51) | CETPGPR119ABCB1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404901-A1 | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2229356-B1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | disclosed |